Paroxysmal supraventricular tachycardia is defined as tachycardia originating in the atrial or atrioventricular junctional zone, mostly due to folding excitation. It is characterized by paroxysmal panic attacks that stop abruptly. During the attack, the patient feels that the heart is beating very fast and violently, as if it is about to jump out. Some patients may experience fluctuations in blood pressure due to panic during the attack, and elderly and frail patients may even experience a drop in blood pressure. If there is a history of coronary artery disease or other heart disease, there may also be dizziness, weakness, dyspnea, angina, syncope, and electrocardiogram suggestive of myocardial ischemic changes. In most cases, the presence of atrioventricular bypass, or differences in conduction and nonresponsiveness in AV node function, underlie its occurrence. Although simple episodes of paroxysmal supraventricular tachycardia are generally not life-threatening, they are symptomatic and have a greater impact on quality of life, but in patients with concomitant organic heart disease, simple episodes of supraventricular tachycardia can increase the risk of disease progression. It should be particularly emphasized that in women patients during pregnancy, episodes of supraventricular tachycardia may lead to intrauterine hypoxia in the fetus, with the risk increasing the later in the pregnancy, and that there is a potential risk to the fetus during pregnancy, whether treated with medication or surgery, a condition that needs to be prevented in advance. Paroxysmal supraventricular tachycardia is characterized by sudden onset and cessation, and in many cases the attack has been terminated when the patient arrives at the hospital, and the important clinical evidence to confirm the diagnosis is the electrocardiogram at the time of the attack, resulting in multiple episodes of panic and palpitations but not confirming the diagnosis. In episodes of paroxysmal supraventricular tachycardia, intravenous antiarrhythmic drugs are effective in terminating the episodes but not in achieving a cure. Oral antiarrhythmic drugs have limited effect in preventing further episodes, and the effect of the drugs themselves on the patient’s heart rhythm may affect the patient’s quality of life. The treatment of choice is minimally invasive radiofrequency catheter ablation. The catheter ablation process only requires the patient’s venous system to be punctured, and the catheter is placed into different locations in the heart chambers to induce, confirm, localize and treat supraventricular tachycardia, and the whole process takes about one hour. In recent years, the newly introduced three-dimensional scalar ablation system for the treatment of supraventricular tachycardia uses the three-dimensional electric field magnetic field to assist in locating the heart chambers and catheters, replacing the traditional X-ray fluoroscopy two-dimensional image, which makes the surgical positioning more accurate and can reduce the intraoperative X-ray fluoroscopy dose by more than 90% while increasing the surgical safety factor. It is especially suitable for the treatment of weak or radiation-sensitive patients, and is called “green surgery”.